Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Dec;70(6):1171–1175. doi: 10.1038/bjc.1994.467

Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.

B Chevallier 1, M Marty 1, J M Paillarse 1
PMCID: PMC2033669  PMID: 7981071

Abstract

This double-blind multicentre study has been carried out in order to confirm the improvement of ondansetron's antiemetic efficacy when combined with a corticosteroid and to determine whether this increased efficacy is maintained over three chemotherapy courses. One hundred and two patients receiving their first course of cisplatin (50-120 mg m-2)-containing chemotherapy were randomised to receive one of the two following treatments: 8 mg OND i.v. injection and 120 mg MPD i.v. injection before chemotherapy, followed 8-12 h later by an 8 mg OND tablet and a 16 mg MPD tablet (oral treatment administered twice daily for 3-5 days): or 8 mg OND plus placebo i.v. injection before chemotherapy, followed by 8-12 h later by an 8 mg OND tablet and placebo p.o. (oral treatment administered twice daily for 3-5 days). The number of emetic episodes (EEs = vomits + retches) and the grade of nausea were recorded. Of the 101 patients studied (efficacy analysis), complete or major control (0-2 EEs) was experienced in 90.4% of patients in the first 24 h in the OND/MPD group compared with 71.4% of patients in the OND group during the first course. This difference in favour of OND/MPD was noted over the three courses and is statistically significant. In the control of delayed emesis (worst day between days 2 and 6) there is a trend in favour of the OND/MDP group during the first course [56.2% vs 43.2% for complete response (no emetic episodes)] which was statistically significant on courses 2 and 3. The global antiemetic control over the course was always in favour of OND/MPD, which leads to a better efficacy maintained over the three courses. Both treatments were well tolerated. The results of this study confirm the increased antimetic efficacy of ondansetron and methylprednisolone in combination in cisplatin-induced acute and delayed emesis which led to a better maintained efficacy over three repeated chemotherapy courses.

Full text

PDF
1172

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. De Mulder P. H., Seynaeve C., Vermorken J. B., van Liessum P. A., Mols-Jevdevic S., Allman E. L., Beranek P., Verweij J. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med. 1990 Dec 1;113(11):834–840. doi: 10.7326/0003-4819-113-11-834. [DOI] [PubMed] [Google Scholar]
  2. Dicato M. A., Kaasa S., Campora E., Bleiberg H., Warnier P., Vindevoghel A., Cunningham D., Liebhard A., Upadhyaya B. K. Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: a randomized, single-blind, multicentre study. The Ondansetron International Emesis Study Group. Clin Oncol (R Coll Radiol) 1992 Sep;4(5):275–279. doi: 10.1016/s0936-6555(05)81098-2. [DOI] [PubMed] [Google Scholar]
  3. Hainsworth J., Harvey W., Pendergrass K., Kasimis B., Oblon D., Monaghan G., Gandara D., Hesketh P., Khojasteh A., Harker G. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991 May;9(5):721–728. doi: 10.1200/JCO.1991.9.5.721. [DOI] [PubMed] [Google Scholar]
  4. Hellenbrecht D., Saller R. Dose-response relationships of the objective and subjective antiemetic effects and of different side effects of metoclopramide against cisplatin induced emesis. Arzneimittelforschung. 1986 Dec;36(12):1845–1849. [PubMed] [Google Scholar]
  5. Kris M. G., Gralla R. J., Tyson L. B., Clark R. A., Cirrincione C., Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989 Jan;7(1):108–114. doi: 10.1200/JCO.1989.7.1.108. [DOI] [PubMed] [Google Scholar]
  6. Kris M. G., Gralla R. J., Tyson L. B., Clark R. A., Kelsen D. P., Reilly L. K., Groshen S., Bosl G. J., Kalman L. A. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer. 1985 Feb 1;55(3):527–534. doi: 10.1002/1097-0142(19850201)55:3<527::aid-cncr2820550310>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  7. Marty M., Pouillart P., Scholl S., Droz J. P., Azab M., Brion N., Pujade-Lauraine E., Paule B., Paes D., Bons J. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990 Mar 22;322(12):816–821. doi: 10.1056/NEJM199003223221205. [DOI] [PubMed] [Google Scholar]
  8. Roila F., Tonato M., Cognetti F., Cortesi E., Favalli G., Marangolo M., Amadori D., Bella M. A., Gramazio V., Donati D. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991 Apr;9(4):675–678. doi: 10.1200/JCO.1991.9.4.675. [DOI] [PubMed] [Google Scholar]
  9. Seynaeve C., Schuller J., Buser K., Porteder H., Van Belle S., Sevelda P., Christmann D., Schmidt M., Kitchener H., Paes D. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer. 1992 Jul;66(1):192–197. doi: 10.1038/bjc.1992.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Smith D. B., Newlands E. S., Rustin G. J., Begent R. H., Howells N., McQuade B., Bagshawe K. D. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet. 1991 Aug 24;338(8765):487–490. doi: 10.1016/0140-6736(91)90555-4. [DOI] [PubMed] [Google Scholar]
  11. Smyth J. F., Coleman R. E., Nicolson M., Gallmeier W. M., Leonard R. C., Cornbleet M. A., Allan S. G., Upadhyaya B. K., Bruntsch U. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ. 1991 Dec 7;303(6815):1423–1426. doi: 10.1136/bmj.303.6815.1423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Soukop M., McQuade B., Hunter E., Stewart A., Kaye S., Cassidy J., Kerr D., Khanna S., Smyth J., Coleman R. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology. 1992;49(4):295–304. doi: 10.1159/000227060. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES